Get insights on Biogen’s Leqembi sales outlook, clinical value, risks, and what new drug approvals may mean for investors.

Days after Johnson & Johnson’s posdinemab failed to slow clinical decline in patients with Alzheimer’s disease, Eisai Chief ...

If you are wondering whether Eisai is quietly becoming a value opportunity or just a value trap, you are in the right place to unpack what the current share price is really implying. The stock has ...

If approved, patients could self-administer a weekly dose at home as an alternative to hospital intravenous dosing.

Long-term LEQEMBI treatment suggests potential to delay disease progression from Mild Cognitive Impairment (MCI) to moderate ...

Eisai officially launched its new U.S. headquarters just as the Japanese pharma looks to expand its commercial presence with an Aduhelm follow-up in Alzheimer’s disease by “building trust with the ...

Eisai’s work to develop Alzheimer’s drug Leqembi has brought an effective treatment to patients, making it one of Fast Company’s Most Innovative Companies in medicines and therapeutics. For the ...

Eisai (ESALY) and Biogen (BIIB) announced that the latest findings on time savings with continued treatment with humanized ...

Sisterhood is at the core of Eisai’s awareness campaign for endometrial cancer. The digital and social effort "Spot Her" encourages women to not only look for the signs themselves—spotting and ...

Eisai now has the most detailed look yet at the clinical trial data for its Alzheimer’s disease drug lecanemab, with results showing reductions in telltale disease indicators and a slowing of clinical ...

If approved, lecanemab would be the first and only anti-amyloid treatment in Japan to offer an at-home injection from the initiation of treatment for this progressive, relentless disease TOKYO and ...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito) today announced that new data on anti-tau antibody etalanetug ...